MOSCOW, February 20 – RIA Novosti. The decision to conduct a study of the EpiVacCorona vaccine on children has not yet been made, said Rinat Maksyutov, Director General of the Vector State Scientific Center for Virology and Biotechnology, Rospotrebnadzor.
“With regard to children, we are talking about the need for additional clinical studies, sequential, starting from the age of 15-17 years and below, up to the youngest age – infants up to 6 months. Currently, the decision on the need for such clinical studies has not yet been made.” , – said Maksyutov on the air of the TV channel “Russia 24”. The spread of coronavirus